Hepatic encephalopathy: From pathophysiology to treatment

Digestion

Volumn 73, Issue SUPPL. 1, 2006, Pages 86-93

  Mas, Antoni ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Cirrhosis; Hepatic encephalopathy; Pathophysiology

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMMONIA; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; BENZOIC ACID; BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUMAZENIL; LEVODOPA; MANGANESE; NEUROSTEROID; NEUROTOXIN; PSYCHOTROPIC AGENT;

ALBUMIN DIALYSIS; CLINICAL FEATURE; COMA; CONSTIPATION; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG CONTRAINDICATION; DRUG INDICATION; ELECTROLYTE DISTURBANCE; FLAPPING TREMOR; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEPATIC COMA; HEPATIC ENCEPHALOPATHY; HUMAN; INTESTINE ABSORPTION; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER LEVEL; METABOLIC ENCEPHALOPATHY; NEUROIMAGING; NEUROTRANSMISSION; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN INTAKE; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

AMMONIA; ANTI-BACTERIAL AGENTS; ANTIPSYCHOTIC AGENTS; BRAIN; HEPATIC ENCEPHALOPATHY; HUMANS; NEUROTRANSMITTER AGENTS; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; RECEPTORS, GABA-A; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME;

EID: 33644559701     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089783     Document Type: Review

References (38)

1. Córdoba J, Blei AT: Hepatic encephalopathy; in Schiff ER, Sorrell MF, Maddrey WC (eds): Schiff's Diseases of the Liver. Philadelphia, Lippincott Williams & Wilkins, 2003, pp 595-623.
2. Ferenci P, Lockwood A, Mullen K, Terter R, Weissenborn K, Blei AT et al: Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification. Final Report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna 1998. Hepatology 2002;35:716-721.
3. Butterworth RF: The neurobiology of hepatic encephalopathy. Semin Liver Dis 1996;16:235-244.
4. Jones EA: Ammonia, the GABA neurotransmitter system, and hepatic encephalopathy. Metab Brain Dis 2002;17:275-281.
5. Haussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S: Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 2000;32:1035-1038.
6. Kramer L, Tribl B, Gendo A, Zauner C, Schneider B, Ferenci P et al: Partial pressure of ammonia versus ammonia in hepatic encephalopathy. Hepatology 2000;31:30-34.
7. Lockwood AH, McDonald JM, Rieman RE, Gelbard AS, Laughlin JS, Duffy TE et al: The dynamics of ammonia metabolism in man. Effects of liver disease and hyperammonemia. J Clin Invest 1979;63:449-460.
8. Watanabe A, Takei N, Higashi T, Shiota T, Nakatsukasa H, Fujiwara M et al: Glutamic acid and glutamine levels in serum and cerebrospinal fluid in hepatic encephalopathy. Biochem Med 1984;32:225-231.
9. Butterworth RF: Hepatic encephalopathy: a neuropsychiatric disorder involving multiple neurotransmitter systems. Curr Opin Neurol 2000;13:721-727.
10. Vasconez C, Elizalde JI, Llach J, Ginès A, de la Rosa C, Fernández RM et al: Helicobacter pylori, hyperammonemia and subclinical porto-systemic encephalopathy: effects of eradication. J Hepatol 1999;30:260-264.
11. Blei AT: Hepatic encephalopathy; in Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodés J (eds): Oxford Textbook of Clinical Hepatology, ed 2. Oxford, Oxford Medical, 1999, pp 765-783.
12. Ahboucha S, Butterworth RF: Pathophysiology of hepatic encephalopathy: a new look at GABA from the molecular standpoint. Metab Brain Dis 2004;19:331-343.
13. 1H-magnetic resonance in the study of hepatic encephalopathy in humans. Metab Brain Dis 2002;17:415-429.
14. Clemmesen JO, Larsen FS, Kondrup J, Hansen BE, Ott P: Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 1999;29:648-653.
15. Butterworth RF: Pathogenesis of hepatic encephalopathy: new insights from neuroimaging and molecular studies. J Hepatol 2003;39:278-285.
16. Conn HO, Leevy CM, Vhlacevic ZR, Rodgers JB, Maddrey WB, Seeff L et al: Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double-blind controlled trial. Gastroenterology 1977;72:573-583.
17. Bustamante J, Rimola A, Ventura PJ, Navasa M, Cirera I, Reggiardo V et al: Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999;30:890-895.
18. Vaquero J, Chung C, Cahill ME, Blei AT: Pathogenesis of hepatic encephalopathy in acute liver failure. Semin Liver Dis 2003;23:259-269.
19. Shawcross DL, Davies NA, Williams R, Jalan R: Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004;40:247-254.
20. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R: The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000;32:734-739.
21. Blanc P, Daurès JP, Liautard J, Buttigieg R, Desprez D, Pageaux G et al: Association lactulose-néomycine versus placebo dans le traitement de l'encéphalopathie hépatique aiguë. Résultats d'un essai contrôlé randomisé. Gastroentérol Clin Biol 1994;18:1063-1068.
22. Scarpignato C, Pelosini, I: Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005;51(suppl 1):36-66.
23. Zeneroli ML, Avallone R, Corsi L, Venturini I, Baraldi C, Baraldi M: Management of hepatic encephalopathy; role of rifaximin. Chemotherapy 2005;51(suppl 1):90-95.
24. Als-Nielsen B, Gluud LL, Gluud C: Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004;328:1046-1051.
25. Córdoba J, López-Hellín J, Planas M, Sabín P, Sanpedro F, Castro F: Normal diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004;41:38-43.
26. Blei AT, Córdoba J: Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. Am J Gastroenterol 2001;96:1968-1976.
27. García-Tsao G: Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004;18:353-372.
28. Kircheis G, Wettstein M, Dahl S, Hausinger D: Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy. Metab Brain Dis 2002;17:453-462.
29. Marchesini G, Fabbri A, Bianchi G, Brizi M, Zoli M: Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology 1996;23:1084-1092.
30. Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS: Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomised trial. Hepatology 1992;16:138-144.
31. Als-Nielsen B, Kjaergard LL, Gluud C: Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy. Cochrane Database Syst Rev 2001;4:CD002798.
32. Als-Nielsen B, Gluud L, Gluud C: Dopaminergic agonists for hepatic encephalopathy. Cochrane Database Syst Rev 2004;4:CD003047.
33. Als-Nielsen B, Koretz RL, Kjaergard LL, Gluud C: Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst Rev 2003;2:CD001939.
34. Jalan R, Sen S, Williams R: Prospects for extracorporeal liver support. Gut 2004;53:890-898.
35. Hassanein T, Tofteng F, Brown RS Jr, McGuire BM, Lynch P, Mehta R et al: Efficacy of albumin dialysis (MARS) in patients with cirrhosis and advanced grades of hepatic encephalopathy: a prospective, controlled, randomized multicenter trial. Hepatology 2004;40(suppl 1):726A-727A.
36. Demetriou AA, Brown RS Jr, Busuttil RW, Fair J, McGuire BM, Rosenthal P et al: Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004;239:660-667.
37. Samuel D, Ichai P, Feray C, Saliba F, Azoulay D, Arulnaden JL et al: Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation. Transplantation 2002;73:257-264.
38. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C: Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA 2003;289:217-222.